Radioiodine therapy for thyroid cancer

Thyroid Cancer (Second Edition)

Volumn , Issue , 2005, Pages 95-126

  Dietlein, M ^a   Moka, D ^a   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891453243     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-27845-1_6     Document Type: Chapter

References (96)

1. Allweiss P, Braunstein GD, Kate A et al. (1984) Sialadenitis following I-131 therapy for thyroid cancer. J Nucl Med 25:755-758
2. Al-Nahhas AM (1999) Ablation in differentiated thyroid carcinoma: How much surgery? How much iodine? [Editorial] Nucl Med Commun 20:595-597
3. Arnstein NB, Carey JE, Spaulding SA et al. (1986) Determination of iodine-131 diagnostic dose for imaging metastatic thyroid cancer. J Nucl Med 27:1764-1769
4. Beierwaltes WH (1978) The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79-94
5. Beierwaltes WH, Rabbani R, Dmuchowski C et al. (1984) An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 25:1287-1293
6. Berg G, Lindstedt G, Suurküla M et al. (2002) Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 25:44-52
7. Biersack HJ, Helpap B, Koch U et al. (1983) Should treatment of highly differentiated thyroid carcinoma be conservative? Nuklearmedizin 20:20-23
8. 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:231-236
9. Bohuslavizki KH, Klutmann S, Brenner W et al. (1998) Salivary gland protection by ami-fostine in high-dose radioiodine treatment: result of a double-blind placebo-controlled study. J Clin Oncol 16:3542-3549
10. Brown AP, Greening WP, McCready VR et al. (1984) Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 57:323-327
11. Casara D, Rubello D, Saladini G et al. (1993) Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626-1631
12. Casara D, Rubello D, Saladini G et al. (1993) Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations. Eur J Nucl Med 20:192-194
13. 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. J Nucl Med 40:1716-1721
14. Chiu AC, Delpassand ES, Sherman SI (1997) Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82:3637-3642
15. 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nucl Med Commun 17:687-691
16. Comtois R, Theriault C, Del Vecchio P (1993) Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 34:1927-1930
17. Daumerie C, Vynckier S, Caussin J et al. (1996) Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid 6:301-304
18. Dietlein M, Dressler J, Farahati J et al. (2004) Procedure Guidelines for radioiodine therapy of differentiated thyroid cancer (version 2) (in German). Nuklearmedizin 43:115-120
19. Dottorini ME, Lomuscio G, Mazzucchelli L et al. (1995) Assessment of female fertility and carcinogenesis after I-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36:21-27
20. Edmonds CJ, Smith T (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59:45-51
21. Farahati J, Reiners C, Stuschke M et al. (1996) Differentiated thyroid cancer: impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). C a n c er 7 7:17 2-18 0
22. Grüning T, Tiepolt C, Zöphel K, et al. (2003) Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur J Endocrinol 148:395-402
23. Grünwald F, Menzel C, Bender H et al. (1998) Redifferentiation therapy-induced radioio-dine uptake in thyroid cancer. J Nucl Med 39:1903-1906
24. Harbert JC (1987) Nuclear medicine therapy. Thieme, New York
25. Haugen BR (1999) Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34-41
26. Haugen BR, Larson LL, Pugazhenthi U, et al. (2004) Retinoic acid and retinoid receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272-280
27. Haugen BR, Pacini F, Reiners C et al. (1999) A comparison of recombinant human thyro-tropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877-3885
28. Hay ID, Grant CS, van Heerden JA et al. (1992) Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112:1139-1147
29. Hedinger C, Williams ED, Sobin LH (1989) The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63:908-911
30. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. (2003) Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 30:1077-1086
31. Jeevanram RK, Shah DH, Sharma M et al. (1986) Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patient. Nucl Med Biol 13:277-279
32. Keizer de B, Brans B, Hoekstra A, et al. (2003) Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotro-pin before radioiodine therapy. Eur J Nucl Med Mol Imaging30:367-373
33. Kemmer W, Michalczak H (2003) Richtlinie Strahlenschutz in der Medizin 2002. Hildegard Hoffmann, Berlin
34. Ladenson PW, Braverman LE, Mazzaferri EL et al. (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896
35. Lin JD, Chaa TC, Huang MJ et al. (1998) Use of radioactive iodine for thyroid remnant ablation in well differentiated thyroid carcinoma to replace thyroid re-operation. Am J Clin Oncol 21:77-81
36. Lippi F, Capezzone M, Angelini F et al. (2001) Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 144:5-11
37. Löffler M, Weckesser M, Franzius C et al. (2003) Iodine excretion during stimulation with rh TSH in differentiated thyroid carcinoma. Nuklearmedizin 42:240-243
38. Lushbaugh CC, Casarett GW (1976) The effects of gonadal radiation in clinical radiation t herapy. A rev iew. Ca ncer 37:1111-1120
39. Luster M, Lassmann M, Haenscheid H et al. (2000) Use of recombinant human thyrotro-pin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640-3645.
40. 131I therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer 47:664-671
41. Maruca J, Santner S, Miller K et al. (1984) Prolonged iodine clearance with a depletion regimen for thyroid carcinoma. J Nucl Med 25:1089-1093
42. Massin JP, Savoie JC, Garnier H et al. (1984) Pulmonary metastases in differentiated thyroid carcinoma. Cancer 53:982-992
43. Maxon HR, Boehringer TA, Drilling J (1983) Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 8:123-126
44. Maxon HR, Englaro EE, Thomas SR et al. (1992) Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33:1132-1136
45. Maxon HR, Thomas SR, Hertzberg VS et al. (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937-941
46. Mazzaferri EL (1995) Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 80:1485-1487
47. Mazzaferri EL (1996) Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD (eds) The thyroid. Lippincott-Raven, Philadelphia, pp 922-945
48. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgery and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
49. Mazzaferri EL, Robbins RJ, Spencer CA et al. (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441
50. Mazzaferri EL, Young E (1981) Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511-518
51. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 18:505-512
52. Menzel C, Grünwald F, Schomburg A et al. (1996) "High- dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 37:1496-1503
53. Morris JC, Kim CK, Padilla ML et al. (1997) Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy. Thyroid 7:63-66
54. Moser E, Fritsch S, Braun S (1988) Thyroglobulin and 131 I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy. Nucl Med Commun 9:262-266
55. Nemec J, Zamrazil V, Pohunkova D et al. (1979) Radioiodine treatment of pulmonary metastases of differentiated thyroid cancer. Results and prognostic factors. Nuklearmedizin 18:86-90
56. Nostrand van DV, Neutze J, Atkins F (1986) Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27:1519-1527
57. Pacini F, Gasperi M, Fugazzda L et al. (1994) Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 35:1418-1422
58. Pacini F, Lippi F, Formica N et al. (1987) Therapeutic doses of iodine-131 reveal undiag-nosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888-1891
59. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068
60. Park HM, Perkin OW, Edmondson JW et al. (1994) Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4:49-54
61. Park JT II, Hennessey JV (2004) Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rh TSH scanning in patients taking levothyroxine. Thyroid 14:57-63
62. Pellegriti G, Scollo C, Giuffrida D et al. (2001) Usefulness of recombinant human thyro-tropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 11:1025-1030
63. Pineda JD, Lee T, Ain K et al. (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80: 1488-1492
64. Pons F, Carrio I, Estorch M et al. (1987) Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 12:644-647
65. Ramacciotti C, Pretorius HT, Line BR et al. (1982) Ablation of non-malignant thyroid remnants with low doses of radioiodine: concise communication. J Nucl Med 23:483-489
66. Reiners C (1991) Stochastische Risiken der I-131-Therapie des Schilddrüsenkarzinoms. Nuklearmediziner 20:331-334
67. Robbins J (1991) Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115:133-147
68. Robbins RJ, Larson SM, Sinha N et al. (2002) A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid ablation. J Nucl Med 43:1482-1488
69. Ronga G, Fiorentino A, Paserio E et al. (1990) Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the postsurgical follow-up of differentiated thyroid carcinoma? J Nucl Med 31:1766-1771
70. Rubino C, Vathaire F de, Dottorini ME et al. (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644
71. Samaan NA, Schultz PN, Haynie TP et al. (1985) Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60:376-380
72. Samaan NA, Schultz PN, Hickey R et al. (1992) The results of various modalities of treatment of well-differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720
73. 131I for thyroid cancer. J Nucl Med 17:460-464
74. Schicha H, Dietlein M, Scheidhauer K (1999) Therapie mit offenen radioaktiven Stoffen. In: Büll U, Schicha H, Biersack HJ et al. (eds) Nuklearmedizin. Thieme, Stuttgart, pp 512-545
75. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma (review). N Engl J Med 338:297-306
76. Schlumberger M, Berg G, Cohen O et al. (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105-112
77. Schlumberger M, Challeton C, de Vathaire F et al. (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598-605
78. Schlumberger M, de Vathaire F, Ceccarelli C et al. (1996) Exposure of radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606-612
79. Schlumberger M, Tubiana M, De Vathaire F et al. (1986) Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960-967
80. Schober O, Günter HH, Schwarzrock R et al. (1987) Hämatologische Langzeitveränderungen bei der Radioiodtherapie des Schilddrüsenkarzinoms. I.) Periphere Blutbildveränderungen. Strahlenther Onkol 163:464-474
81. Seabold JE, Ben-Haim S, Pettit WA et al. (1993) Diuretic-enhanced I-131 clearance after ablation therapy for differentiated thyroid cancer. Radiology 187:839-842
82. Simon D, Köhrle J, Schmutzler C et al. (1996) Redifferentiation therapy of differentiated thyroid carcinoma with retinoid acid: basics and first clinical results. Exp Clin Endocri-nol Diabetes 104 [Suppl 4]:13-15
83. Simon D, Körber C, Krausch M et al. (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 29:775-782
84. Sisson JC, Jamadar DA, Kazerooni EA et al. (1998) Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid 8:215-221
85. Solans R, Bosch J-A, Galofré P et al. (2001) Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42:738-743
86. Solomon BL, Wartowsky L, Burman KD (1996) Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 81:333-339
87. Spiegel W, Reiners C, Börner W (1985) Sialadenitis following iodine-131 therapy for thyroid carcinoma [letter]. J Nucl Med 26:816
88. Strahlenschutzkommission (2004) Notwendigkeit der stationären Durchführung der Ganzkörperszintigraphie mit I-131 beim Schilddrüsenkarzinom. Empfehlung der Strahlenschutzkommission. Verabschiedet in der 190. Sitzung der Strahlenschutzkom-mission am 22/23. April 2004
89. Strahlenschutzverordnung 2001 (2002) Bundesanzeiger, Köln
90. Sweeney DC, Johnston GS (1995) Radioiodine therapy for thyroid cancer. Endocrinol Metabol Clin North Am 24:803-839
91. 131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 83:2675-2680
92. Varma VM, Beierwaltes WH, Nofal MM et al. (1970) Treatment of thyroid cancer: death rates after surgery and after surgery followed by sodium iodine I-131. JAMA 214:1437-1442
93. Varma VM, Dai WL, Henkin RI (1992) Taste dysfunction in patients with thyroid cancer following treatment with I-131. J Nucl Med 33:996
94. Wittekind C, Meyer JH, Bootz F (2003) TNM Klassifikation maligner Tumoren. 6. Aufl. Springer, Berlin Heidelberg New York
95. Wong JB, Kaplan MM, Meyer KB et al. (1990) Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 19:741-760
96. Zettinig G, Hanselmayer G, Fueger BJ et al. (2002) Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging 29:1428-1432